The Australian Stock Exchange has denied claims by ISignthis that it suspended the fintech company’s shares without warning and at the direction of ASIC, but has admitted that it told the company it would consult with the securities regulator before lifting the ongoing suspension.
Zango hits back at Domain lawsuit, says ads were ‘puffery’
Otsuka, Bristol-Myers can withdraw admissions in Abilify damages case
A judge has granted a request by Otsuka and Bristol-Myers Squibbs to withdraw admissions in proceedings brought by Generic Health seeking damages, after the generic drug maker was temporarily blocked from selling a generic version of antipsychotic Abilify in a patent dispute in which it ultimately triumphed.